Long-term Safety and Tolerability of AFFITOPE AD02

Affiris AG23 enrolled

Overview

The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE AD02 applied during AFFiRiS 002

Study Type

OBSERVATIONAL

Enrollment

Conditions

Alzheimer's Disease

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent signed and dated by patient and caregiver * Patients having participated in AFF002 and having received at least 1 vaccination with AFFITOPE AD02 * Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits Exclusion Criteria: * Patients having received no vaccination with AFFITOPE AD02 * History of questionable compliance to visit schedule, patients not expected to finish the clinical trial

Locations (1)

Ordination Schmitz

Vienna, Austria

Outcomes

Primary Outcomes

Long-term tolerability

Time frame: 1 year

Secondary Outcomes

Clinical and immunological efficacy (evaluated in an explorative manner only)

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.